Replies to post #217541 on Biotech Values

[DewDiligence]

MYL, RVNC collaborate on Botox biosimilar for global development—$25M up-front for RVNC:

http://investors.revance.com/releasedetail.cfm?ReleaseID=1059139

Mylan N.V. and Revance Therapeutics, Inc. today announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX.

…The companies plan to work together to gain regulatory approval in the development of this important biosimilar product, and commercialize this product in the U.S., Europe and applicable markets throughout the rest of the world. The collaboration includes an upfront payment of $25 million to Revance, with contingent milestone payments upon achievement of additional clinical, regulatory and sales targets, plus sales royalties in all relevant markets.

I wasn't expecting this and I'm not yet sure if I like it.

RVNC's 4Q17 CC is now. Should be a good listen.